These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 25932758)

  • 21. [Combination of beta-1 agonist and corticosteroid is advantageous not only in asthma. COPD patients spared exacerbations].
    MMW Fortschr Med; 2002 Oct; 144(44):55. PubMed ID: 12494604
    [No Abstract]   [Full Text] [Related]  

  • 22. [Management of acute exacerbation of chronic obstructive pulmonary disease (COPD)].
    Gillissen A; Buhl R; Kardos P; Kenn K; Matthys H; Pfister R; Rabe KF; Sauer R; Vogelmeier C; Wettengel R; Worth H; Menz G
    Dtsch Med Wochenschr; 2003 Aug; 128(33):1721-7. PubMed ID: 12920671
    [No Abstract]   [Full Text] [Related]  

  • 23. Effect of the CXCR2 antagonist danirixin on symptoms and health status in COPD.
    Lazaar AL; Miller BE; Tabberer M; Yonchuk J; Leidy N; Ambery C; Bloomer J; Watz H; Tal-Singer R
    Eur Respir J; 2018 Oct; 52(4):. PubMed ID: 30139779
    [No Abstract]   [Full Text] [Related]  

  • 24. Evidence on the identity of the CXCR2 antagonist AZD-5069.
    Norman P
    Expert Opin Ther Pat; 2013 Jan; 23(1):113-7. PubMed ID: 22992174
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial.
    Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Anzueto A; Alagappan VK; Siddiqui S; Rekeda L; Miller CJ; Zetterstrand S; Reisner C; Rennard SI
    Am J Respir Crit Care Med; 2016 Sep; 194(5):559-67. PubMed ID: 27585384
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bronchodilator safety in chronic obstructive pulmonary disease-reply.
    Stanbrook MB; Campitelli M; Gershon A
    JAMA Intern Med; 2014 Apr; 174(4):648. PubMed ID: 24711200
    [No Abstract]   [Full Text] [Related]  

  • 27. [Inhalation anti-asthmatic agents--efficient in chronic obstructive pulmonary disease?].
    Gulsvik A
    Tidsskr Nor Laegeforen; 2003 Oct; 123(19):2720-2. PubMed ID: 14600745
    [No Abstract]   [Full Text] [Related]  

  • 28. Bronchodilator safety in chronic obstructive pulmonary disease: time to focus?
    van Dijk WD; Käyser SC
    JAMA Intern Med; 2014 Apr; 174(4):647. PubMed ID: 24711198
    [No Abstract]   [Full Text] [Related]  

  • 29. Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial.
    Rabe KF; Bateman ED; O'Donnell D; Witte S; Bredenbröker D; Bethke TD
    Lancet; 2005 Aug 13-19; 366(9485):563-71. PubMed ID: 16099292
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sputum eosinophilia and the short term response to inhaled mometasone in chronic obstructive pulmonary disease.
    Brightling CE; McKenna S; Hargadon B; Birring S; Green R; Siva R; Berry M; Parker D; Monteiro W; Pavord ID; Bradding P
    Thorax; 2005 Mar; 60(3):193-8. PubMed ID: 15741434
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [New studies refute steroid opponents. COPD--after all a case for corticosteroids?].
    Calverley P
    MMW Fortschr Med; 2003 Jun; 145(24):20. PubMed ID: 12866294
    [No Abstract]   [Full Text] [Related]  

  • 32. SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects.
    Holz O; Khalilieh S; Ludwig-Sengpiel A; Watz H; Stryszak P; Soni P; Tsai M; Sadeh J; Magnussen H
    Eur Respir J; 2010 Mar; 35(3):564-70. PubMed ID: 19643947
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Responsible prescribing for asthma and COPD.
    Pearce L
    Nurs Times; 2012 Nov 13-19; 108(46):12, 14, 16. PubMed ID: 23240219
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Methodological issues in therapeutic trials of COPD.
    Kardos P
    Eur Respir J; 2009 Feb; 33(2):443-4. PubMed ID: 19181920
    [No Abstract]   [Full Text] [Related]  

  • 35. Inhaled steroids and COPD.
    Cooper CB; Decramer M
    Eur Respir J; 2008 Aug; 32(2):523-4. PubMed ID: 18669794
    [No Abstract]   [Full Text] [Related]  

  • 36. Non-neuronal cholinergic system contributes to corticosteroid resistance in chronic obstructive pulmonary disease patients.
    Milara J; Cervera A; de Diego A; Sanz C; Juan G; Gavaldà A; Miralpeix M; Morcillo E; Cortijo J
    Respir Res; 2016 Nov; 17(1):145. PubMed ID: 27825347
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined anti CXC receptors 1 and 2 therapy is a promising anti-inflammatory treatment for respiratory diseases by reducing neutrophil migration and activation.
    Planagumà A; Domènech T; Pont M; Calama E; García-González V; López R; Aulí M; López M; Fonquerna S; Ramos I; de Alba J; Nueda A; Prats N; Segarra V; Miralpeix M; Lehner MD
    Pulm Pharmacol Ther; 2015 Oct; 34():37-45. PubMed ID: 26271598
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is There room for Theophylline in COPD?
    Toledo-Pons N; Cosío BG
    Arch Bronconeumol; 2017 Oct; 53(10):539-540. PubMed ID: 28645434
    [No Abstract]   [Full Text] [Related]  

  • 39. Pulmonary nocardiosis in a patient with chronic obstructive pulmonary disease--case report and literature review.
    Anderson M; Kuźniar TJ
    Pneumonol Alergol Pol; 2012; 80(6):565-9. PubMed ID: 23109210
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The MMW Drug Prize 2002: Prize for a new classic with innovation potential].
    Schultze-Werninghaus G
    Med Klin (Munich); 2002 Dec; 97 Suppl 2():1. PubMed ID: 12593173
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.